Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MANBA | O00462 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.33 |
| ▸ | AGL | P35573 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15266072 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL7432236 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL15265936 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL4585300 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL3069911 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL9880695 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL15265566 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL10075956 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL22090238 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL9880689 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144425-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2001-10-17 | — | — | EP | claimed |
| WO-2000042053-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (US) | 2000-07-20 | — | — | WO | claimed |
| EP-4045182-A1 | MICROWAVE-ASSISTED METHOD FOR SYNTHESIS OF OLIGO- AND POLYSACCHARIDES ON SOLID PHASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045180-A1 | DEVICE FOR AUTOMATED SYNTHESIS OF OLIGO- AND POLYSACCHARIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-2640734-A1 | AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | Technion Research & Development Foundation Ltd. (IL) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012066546-A1 | AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2012-05-24 | — | — | WO | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1874788-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-09 | — | — | EP | disclosed |
| EP-1864992-A2 | Monosaccharide derivatives | RANBAXY LABORATORIES, LTD. (IN) | 2007-12-12 | — | — | EP | disclosed |
| EP-1842855-A2 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006111783-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | MANBA 234/4885LMNA 4860/4885THRB 2264/4885 |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, MUC1, FUT5 | MANBA 191/4885LMNA 4864/4885THRB 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.